Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958954 · ClinicalTrials.gov registry record
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
A clinical trial, sponsored by ModernaTX.
- Completed
- Registry status
- 50,000,000
- Enrollment target
NCT04958954: Completed study, sponsored by ModernaTX.
NCT04958954 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 50,000,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04958954 has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 50,000,000 participants
- Enrollment target
Study Summary
The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50,000,000 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2023-06-30 |
What the finished NCT04958954 record still lists
NCT04958954 is an observational study that tracks outcomes without assigning an intervention. Its 50,000,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04958954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04958954 about?
NCT04958954 is a clinical study titled "Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States". The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.
What is the current status of trial NCT04958954?
This trial is currently completed. The enrollment target is 50,000,000 participants. The study started on 2021-07-07. Estimated completion is 2023-06-30.
Who is sponsoring clinical trial NCT04958954?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02485847 · 20,000,000 participants
IRIS Registry: Intelligent Research in Sight Registry
- NCT05678699 · 10,000,000 participants · NA
The Effects of Medicaid Policy Interventions on Racial Equity in Severe Maternal Morbidity
- NCT02693223 · 3,892,063 participants
Get With the Guidelines-Stroke Registry
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI